Mumbai: After the Indian government recently lifted a patent license, Indian pharma major, Cipla, has announced a massive reduction of up to 76 per cent in its cancer drug prices.
Following the move, the price of Cipla's generic kidney cancer drug, Sorafenib, will be available at Rs 6,840 a month from the earlier Rs 27,950.
The lung cancer drug Gestinib price has been cut down by 60 per cent to just over Rs 4000, instead of earlier Rs 10,200.
Temozolamide, a very effective brain tumour treatment drug has come down to Rs 5000 from the original Rs 20,250....more
07:51 AM, May 05, 2012
London: A faulty gene is linked to more than a third of all kidney cancers. The finding will help researchers understand how the cancer develops and may in the future lead to new treatments and earlier diagnosis. Everyone is born with a gene called PBRM1, but in some people it gets damaged during their lifetime, which can lead to cancer, the journal Nature reports. A mutated PBRM1 was found in...
03:38 PM, Jan 20, 2011